Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. John Marshall, Chief, Division of Hematology/Oncology at Georgetown University, and Dr. Tony Shields, Associate Center Director, Clinical Sciences at Karmanos Cancer Center Institute. Both are co-authors on the December 8, 2020 paper: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer found in Clinical Cancer Research, a journal of the American Association for Cancer Research.

In this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa.

For more information, please visit: www.CarisLifeSciences.com/MI-FOLFOXai/